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Primary effusion lymphoma (PEL) is an AIDS-defining cancer. All PELs
carry Kaposi sarcoma-associated herpesvirus (KSHV). X chromosome-
targeted sequencing of PEL identified 34 commonmissensemutations
in 100% of cases. This included a Phe196Ser change in the interleukin
1 receptor-associated kinase 1 (IRAK1). The mutation was verified in
primary PEL exudates. IRAK1 is the binding partner of MyD88, which
is mutated in a fraction of Waldenström macroglobulinemia. To-
gether, these two mediate toll-like receptor (TLR) signaling. IRAK1
was constitutively phosphorylated in PEL and required for survival,
implicating IRAK1 and TLR signaling as a driver pathway in PEL and
as a new drug development target.
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Primary effusion lymphoma (PEL) is a highly aggressive sub-type of diffuse large B-cell lymphoma (DLBCL) (1). With
few exceptions, PEL develops in HIV-positive patients and, if
left untreated, causes death within a few months. All PELs ex-
press the CD138/syndecan-1 marker and carry the Kaposi sar-
coma-associated herpesvirus (KSHV). Approximately 60–90%
of PELs also harbor EBV (reviewed in ref. 2). KSHV is neces-
sary for PEL growth, but unlike EBV, it is not able to transform
mature B cells in culture. PELs are fully transformed. The cells
readily grow in culture and form tumors in nude mice (3, 4). This
suggests that in addition to viral infection, changes in the host
genome also contribute to tumor development. Thus far, no
PEL-specific driver mutations have been identified.
Genomic approaches for PEL lag behind those for other
cancers because of the rarity of the disease. We reasoned that
the rarity was a result of a very defined tumor-devel-
opment pathway. Unlike DLBCL, which has many subtypes,
histological subtypes for PEL have not been described, and we
hypothesized that any driver mutation should be present in 100%
of samples. This hypothesis has been born out at the level of
chromosome copy number variations (5) and transcriptional
profiling (6). A signature translocation such as myc in Burkitt
lymphoma has not been described for PEL. Over the years, we
assembled a large collection of functionally characterized PEL
cells (Table 1), which for this project were augmented with nine
primary patient exudates.
The PEL samples to which we had access developed in male
patients. All PEL cell lines that are available for functional
studies are of male origin. We reasoned that any mutation on
the X chromosome would automatically be hemizygous, and thus
define the phenotype. Any mutation discovered by DNA se-
quencing in a protein-coding region would result in a mutant
protein expressed from that locus, and all mutations are linked in
cis (same haplotype). In contrast, mutations in autosomal regions
could be in the nonexpressed copy of the gene, and many would
be heterozygous. Furthermore, ambivalent nucleotide assign-
ments on chromosome X are most likely the result of sequencing
errors, as prior studies did not find evidence of gene amplifica-
tion of chromosome X. Focusing on chromosome X thus re-
duced the coverage requirement to ascertain single nucleotide
variants (SNVs). Therefore, we conducted targeted profiling of
chromosome X, using the RainDance XSeq panel and technol-
ogy. This panel provides for >98% coverage of 800 known genes
on chromosome X. Coverage spans all exons as well as the 5′
promoter region and 3′ UTR for each gene (7). Using this ap-
proach, we identified, among others, a new mutant in interleukin
1 receptor-associated kinase 1 (IRAK1) as being conserved in
100% of PEL. The mutation introduced a new phosphorylation
site. Experimentally, we showed that constitutive IRAK-1 kinase
activity was essential for PEL survival.
Results
To identify single nucleotide changes on the X chromosome in
PEL, we used targeted resequencing. Targets were enriched
by droplet-PCR (RainDance platform) and then subjected to
next-generation sequencing. We used a discovery set of eight
samples, which were sequenced to a mean coverage depth of
380-fold ± 107-fold, and a second validation set of eight
samples (including primary PEL exudate cells), which were
sequenced to a mean coverage depth of 39-fold ± 15-fold
(Table 1). Overall, we generated 76 Mb of 36-bp single-end
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reads using an Illumina genome analyzer and 209 Mb of 100-
bp paired-end reads using an Illumina HiSeq instrument.
More than 90% of the regions of interest were covered
with a depth of 20× or greater, with no apparent bias for
GC-content (Fig. 1).
In all (n = 16; 100%) samples, 1,915 SNVs were present; of
those, 512 SNVs were located in coding regions. Including 8,304
variants in the coding region, leading to 55 missense mutations,
29,313 SNVs had ≥50% frequency. We did not perform copy
number analysis on the sequencing data, as we previously pub-
lished the copy number profiles of these samples (5).
SNV detection remains challenging because of the high se-
quence error rates. We examined several factors when report-
ing SNVs and indels. Coverage of 30× or higher was required
for each SNV call in accordance with prior work (8). If there
were two variants at the same genomic location, the true vari-
ant reported had to appear at 60% frequency or higher. We
aligned all of the targeted region primer sequences designed to
the reference genome and excluded any variants within the
primer capture sequences. We confirmed the concordance of
known SNVs, using data from Affymetrix single-nucleotide
polymorphism (SNP) arrays (5). As our aim was to find novel
tumor-specific SNVs, we compared our data with those from
Hapmap data release 28, from August 2010, on National
Center for Biotechnology Information B36 assembly, dbSNP
b126, and filtered out common variants. Finally, we validated
individual SNVs by Sanger sequencing. This let to our con-
sensus list of PEL-specific SNVs in chromosome X (Table 2).
To further narrow our results and to identify the most bio-
logically relevant alterations, we used previously published
PEL mRNA profiling data (6, 9) to establish which of our target
genes were transcribed in PEL (Fig. 2). The three genes IRAK1
Phe196Ser, prefoldin subunit 3 (VBP1) Met123Val, and WD
repeat-containing protein 13 (WDR13) 201/199fs were tran-
scribed at high levels in PEL, and each had a novel, PEL-
defining SNV in 100% of samples (P ≤ 0.05, Bonferroni-adjusted
based on a comparison of 800 targeted genes across 16 samples,
assuming a 12% frequency of a new SNV being present in any
one sample by chance). All three genes represent candidate
driver mutations in PEL.
We prioritized further studies on the IRAK1 Phe196Ser
(C587T > C, at nt 153,284,192) mutation, which would in-
troduce a novel phosphorylation site. The mutated residue is
part of a phenylalanine triad and is 100% conserved across
species. The IRAK1 Phe196Ser mutation was present in 13 of
the 16 PELs subjected to targeted next-generation sequenc-
ing. For the remaining three samples, the coverage was too
low to ascertain the mutation. For two of these samples
(CRO-AP3 and CRO-AP5), the mutation was subsequently
confirmed by PCR and Sanger sequencing. We obtained DNA
from eight additional primary PEL cases and sequenced
IRAK1. The IRAK1 Phe196Ser mutation was present in seven
(86%) of these eight primary PEL cases (Table 3). We also
obtained normal tissue from two of the patients, and neither
had the IRAK Phe196Ser mutation. For the PEL cell lines, we
had complete SNV data. Other SNVs in the IRAK1 gene,
which do not change the amino acid sequence, were not
conserved among the PEL samples (Fig. 3). This suggests that
this mutation was selected for and that each case used in this
collection represents an independent sample.
To establish a functional role for these findings, we focused
on IRAK1. IRAK1 mediates toll-like receptor (TLR) and IL-1
receptor signaling (10). IRAK1 expression in PEL was confirmed
Table 1. Sample origin, coverage, and specificity
Samples* All reads On target Specificity Coverage Purpose
BC1 23,121,252 21,691,580 0.94 443 Discovery
BC2 24,444,387 22,385,092 0.92 464 Discovery
BC5 19,576,378 18,062,589 0.93 371 Discovery
BCBL1 25,674,276 24,135,660 0.94 497 Discovery
BCLM 19,605,945 18,085,981 0.92 370 Discovery
BCP1 16,616,184 13,967,038 0.84 289 Discovery
JSC1 10,290,737 9,285,549 0.90 173 Discovery
VG1 23,332,697 21,419,478 0.92 439 Discovery
Mean ± SD 380 ± 107
TY1 4,791,393 4,535,046 0.95 58 Validation
AP2 4,096,685 3,330,357 0.81 42 Validation
AP3 3,017,097 2,445,597 0.81 33 Validation
AP5 3,703,516 3,385,599 0.91 45 Validation
BC3 2,349,785 1,800,776 0.77 24 Validation
Patient 1 4,535,193 4,377,692 0.97 59 Validation
HHB2 3,057,278 2,698,232 0.88 31 Validation
ISI1 1,830,663 1,496,222 0.82 20 Validation
Mean ± SD 39 ± 15
*Sample origin is described in Roy et al. (5).
Fig. 1. Individual quality control (QC) of droplet-PCR enrichment and se-
quencing. Shown are six density curves representing the distribution of (A)
the predicted amplicon length in the PCR, (B) the read-count per amplicon,
(C) the GC-content across all PCR amplicons, (D) the mean coverage, (E) the
minimal coverage, and (F) the maximal coverage on each position using the
read data for the VG1 PEL as an example. (G) Coverage by GC-content.
Shown are n = 8 samples and how coverage changes with amplicon
GC-content. Data were from the discovery, single-lane multiplexed QC run,
not the final data set, which includes additional sequencing runs. The final
coverage is reported in Table 1. The vertical axis shows coverage on a log10
scale; the horizontal axis shows the %GC-content of each amplicon. Colors
indicate coverage of each amplicon, with bright yellow indicative of higher
and dark red of lower coverage. Note the drooping tail at >70% GC-content in
all samples, which represents the maximal GC-content compatible with this
type of PCR.















by Western blot (Fig. 4A). IRAK2 and IRAK4 were also
expressed, but not the inhibitory IRAK M isoform. Unlike in
BJAB cells, in PEL, IRAK1 was constitutively phosphorylated at
T209, an activation marker residue (11), in the absence of re-
ceptor stimulation (Fig. 4A). Immune fluorescence analysis
demonstrated IRAK1 T209 phosphorylation in about 20% of
BC1 cells. BJAB cells did not show evidence of IRAK1 T209
phosphorylation (Fig. 4B). This experiment was conducted in
the absence of IL-1β. Even though in PEL, IRAK1 was already
phosphorylated at T209 before stimulation (Fig. 5A, lane 1
compared with lanes 3, 5, and 7), upon IL-1β stimulation,
T209 became more phosphorylated. IL-1β-induced IRAK1 T209
phosphorylation increased over time and was observed in multiple
independent PEL cell lines (Fig. 5 A and C, lanes 4, 6, and 8).
This suggests that the IL-1β-signaling pathway in PEL was
functional, but that the activation threshold was lower or that
IL-1β-independent signaling events drive IRAK1 activation in
KSHV-infected cells.
To test the hypothesis that IRAK1 was required for PEL
survival, we diminished IRAK1 expression by shRNAs. Abro-
gation of IRAK1 expression by multiple independent shRNAs
abolished PEL growth in culture (Fig. 5D) and in soft agar (Fig.
5E) and decreased IL-10 secretion (Fig. 5F). IL-10 is expressed
in most PELs and is required for survival (12). BJAB cells were
oblivious to IRAK1 depletion in these assays. Fig. 5G shows the
efficacy of IRAK1 knockdown for two different shRNA con-
structs. These data establish IRAK1Phe196Ser as a novel driver
mutation in PEL.
Table 2. SNVs on chromosome X that change the protein coding region in PEL
Gene AA Change Frequency* mRNA† Name
DHRSX 292, 247 His > Arg, Val > Leu 8/8 nd Dehydrogenase/reductase (SDR family)
ARHGAP6 202, 200 Asn > Lys, Thr > Pro 8/8 No Rho GTPase-activating protein 6
RAI2 202 Met > Val 8/8 No Retinoic acid-induced protein 2
MAGEB2 61 Glu > Lys 8/8 Yes Melanoma-associated antigen B2
TAB3 394 Trp > Arg 8/8 nd TGF-β-activated kinase 1
DMD 477 Arg > Gln 8/8 Yes Dystrophin Dp71ab isoform
RPGR 889,887,878,880 Glu > Gly 8/8 Yes Retinitis pigmentosa GTPase regulator
SSX5 19 Glu > Gln 8/8 Yes Synovial sarcoma, X breakpoint 5
WDR13 325 His > Arg 8/8 Yes WD repeat-containing protein 13
CCDC120 571 Ala > Gly 8/8 nd Coiled-coil domain containing protein 120
MAGIX 112,45‡ His > Arg 8/8 No PDZ domain-containing protein MAGIX
173,97 Phe > Leu
323,247,242 Val > Leu
FAM120C 1083, 1082 Gln > Pro, Ile > Thr¶ 8/8 Yes Family with sequence similarity 120C
MTRNR2L10 3,2 Thr > Pro, Ala 8/8 nd Humanin-like protein 10
ZXDB 764 Asp > Asn 8/8 nd Zinc finger X-linked protein ZXDB
EDA2R 129 Thr > Ala 8/8 No Ectodysplasin A2 receptor
ATP7A 1350 Glu > Lys 8/8 Yes Copper-transporting ATPase
POU3F4 237 Gly > Ala 16/16 Yes POU domain, class 3, factor 4
RNF128 135 Phe > Tyr 8/8 No E3 ubiquitin-protein ligase RNF128
GUCY2F 296 Arg > Gln 8/8 No Retinal guanylyl cyclase 2
LRCH2 398 Asp > Asn 8/8 nd Leucine-rich repeat and calponin homology
domain-containing protein 2723 Arg > Cys
BCORL1 111, 660 Phe > Leu, Val > Gly 16/16 Yes BCL6 corepressor-like protein 1
RAB33A 35 Arg > Gly 8/8 Yes Ras-related protein Rab-33A
DDX26B 843 Ile > Gly 8/8 nd DEAD/H (Asp-Glu-Ala-Asp/His) box
ATP11C 114 Cys > Trp 8/8 nd ATP11C ATPase, class VI, type 11C
MAGEC1 102, 103 Ser > Pro/Cys, P > S 8/8 Yes Melanoma-associated antigen C1
CXorf40A 70 Thr > Ala 8/8 Yes Chromosome X orf40 A
MAGEA10 234, 166 Val > Ile, Arg > Lys 8/8 Yes Melanoma-associated antigen 10
SLC6A8 431,421,316 Asp > Asn 16/16 No Sodium- and chloride-dependent creatine
transporter 1454,444,339 Cys > Arg
504,494,389 Met > Thr
590,580,475 Arg > Cys
592,582,477 Gln > Lys
636,626,521 STOP > Gly
ABCD1 606 Ser > Pro 16/16 Yes ATP-binding cassette subfamily D member 1
635, 712 Val > Met, Arg > His
PLXNB3 1156, 1535 Glu > Asp, Met > Thr 8/8 No Plexin-B3
IRAK1 196 Phe > Ser 8/8 Yes Interleukin 1 receptor kinase 1
VBP1 123 Met > Val 8/8 Yes Prefoldin subunit 3
TCEAL6 175 insC Gln > fs 8/8 nd Transcription elongation factor A-like 6
TEX13A 201 ins,199 ins Trp > fs, Gly > fs 8/8 No Testis-expressed 13A
nd, not determined.
*Number of mutant samples/number of samples with coverage ≥30× (frequency), additional samples had <30× coverage, and even though they often had
the same mutation on confirmatory sequencing, we did not include them here.
†Based on GEO data sets GSE2149 and GDS1063.
‡More than one amino acid position resulting from differential splicing, which generates isoforms.
¶Low coverage.
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Discussion
PEL is a rare viral lymphoma. Although transcriptional profiling
has been done (6, 13), sequencing studies have not, as it has been
exceedingly difficult to obtain enough cases. We collected all
published cell lines as well as nine primary cases for this study.
The use of cell lines allowed us to study the functional con-
sequences of our analysis, which would not have been possible
using only archival specimens.
We and others previously reported karyotyping and compar-
ative genome hybridization (CGH) profiles for some PEL (5, 14–
19). Our prior data were array-based and included a survey of
known SNVs, which was used as a quality control for this study.
Here, we used targeted next-generation sequencing to identify
tumor-specific SNVs. We obtained a large number of signifi-
cantly enriched SNVs in PEL. Each can be considered part of the
mutational signature of PEL and has the potential to contribute
to the PEL phenotype. Detailed validation studies on all candi-
dates are in progress. A limitation of this study is the small
number of cases, although it represents the largest number of
PELs analyzed to date, and even though in two cases, nontumor
tissue did not have the tumor-specific SNV. In an attempt to
address this limitation, we adopted a very stringent threshold
and only report SNVs that were present in >90% of cases. In
comparison, ID3 was identified as a novel driver mutation in
Burkitt lymphoma based on a 30–60% mutation frequency and
five times higher number of cases (20–22).
From a statistical point of view, all the PEL-specific SNVs
represent candidate driver mutations and deserve experimental
follow-up, most notably VBP1 and WDR13, which are abun-
dantly transcribed in PEL. We prioritized IRAK1Phe196Ser be-
cause IRAK inhibitors have entered phase I human clinical
trials. Fifty-five previously identified, noncoding SNVs in the
IRAK1 locus were not conserved; only the single new SNV in-
troducing the IRAK1Phe196Ser mutation was. The IRAK1Phe196Ser
mutation is not a common polymorphism, as recorded in various
SNV databases. This suggests the IRAK1 locus as a whole was
not selected for or fixed by chance in this set of samples; only the
specific single nucleotide substitution was.
The IRAK1Phe196Ser mutation was also present in seven of
eight primary PEL exudate samples, which were never cultured
and thus this mutation potentially represents a driver for growth
in the patient. The IRAK1Phe196Ser variant was constitutively
phosphorylated at T209 in PEL without exogenous stimuli but
could be further phosphorylated in response to IL-1β. At this
point, we do not know the complete phosphorylation pattern of
IRAK1Phe196Ser in PEL.
IRAK1 signaling was required for PEL survival in culture.
The most exciting interpretation of these data would be that
IRAK1Phe196Ser is a gain-of-function mutation and that acti-
vated IRAK1Phe196Ser kinase functions as a novel cell autonomous
oncogene. Indeed, IRAK1Phe196Ser has different biochemical prop-
erties than the wild-type protein. IRAK1 activation is criti-
cally dependent on T209 phosphorylation (11), and T209 was
phosphorylated in PEL in the absence of exogenous stimuli. The
scenario is more complex, however, as IRAK1 is made in at least
three isoforms and is part of a multicomponent signaling com-
plex including MyD88, IRAK4, and various receptors, adaptors,
and possibly even viral proteins. At this point, we do not know
the exact composition of this complex in PEL or whether MyD88
is mutated as well. It may be that the IRAK1Phe196Ser allele is
better at interacting with MyD88, IRAK4, or KSHV trans-
membrane oncogenes (K1, K15) than wild-type IRAK1. In EBV
lymphoma, IRAK1 is essential for mediating LMP1 signaling
(23). In the latter case, any phenotype of IRAK1Phe196Ser would
only be visible in the context of viral infection.
Fig. 2. Heat map of transcription for highly mutated genes in PEL and other
types of DLBCL. The expression values are derived from Affymetrix CEL data
(GEO data set GDS1063). Red color represents high, white intermediate, and
blue low expression levels. The genes shown on the vertical axis are the
subset of the highly mutated genes reported in Table 2. Individual sample
identifiers are shown on the bottom and classes on the top. BL, Burkitt
lymphoma; CB, centroblastic; IB, immunoblastic.
Table 3. IRAK coverage and confirmation
Phe196Ser, c587T > C
(nt 153,284,192)*
Sample Frequency (%)† Coverage (fold) Confirmed‡
BC1 100 154 nd
BC2 100 237 Yes
BC5 100 362 ndd
BCBL1 100 313 Yes
BCP1 100 111 Yes
BCLM 100 141 Yes
JSC1 99.1 225 nd
VG1 100 116 Yes
HHB2 100 13 nd
BC3 100 13 Yes
TY1 100 10 nd
Patient 1 100 11 nd
CRO-AP5 Low¶ 0 Yes
ISI1 Low¶ 0 nd
CRO-AP2 6.25 32 nd
CRO-AP3 Low 0 Yes
Patient 2 —§ — Yes
Patient 3 — — Yes
PEL625# — — Yes
PEL533# — — Yes
PEL534# — — No
PEL535# — — Yes
PEL536# — — Yes
PEL537# — — Yes
Skin# — — No
Spleen# — — No
nd, not determined.
*Human Genome built hg19_2011_07_29.
†Frequency refers to the mutation as percentage of total reads.
‡Confirmed by PCR amplification and direct Sanger sequencing (Phe196Ser)
or PCR amplification, subcloning and Sanger sequencing.
¶Too low coverage to determine.
§PEL DNA from patients was not subjected to next-generation sequencing.
#DNA from HIV+ samples at the AIDS Cancer Specimen Resource.















In addition to PEL, KSHV also causes KS. Case- and family-
based studies in pediatric KS had identified candidate suscepti-
bility genes with immune signaling phenotypes, such as STIM1
and IFN-γR1 (24, 25). Genome-wide association studies for
KS have not been reported to date. As a result of targeted
sequencing of the X chromosome, we identified 55 novel, com-
mon, and by definition homozygous mutations in protein-coding
regions, including IRAK1Phe196Ser. It would be interesting to see
whether these same SNVs are also enriched in KS.
IRAK1 is activated by IRAK4/MyD88 in response to TLR
(except TLR3) and IL-1R signaling. All TLRs are expressed in
PEL and control KSHV reactivation (26). B cells from KSHV
transgenic mice are hyperresponsive to TLR signaling (27). KSHV
encodes a micro-RNA, mir-K12-9, which targets the IRAK1 3′
UTR (28). The mir-K12-9 is expressed in most PEL, and as shown
here, so is IRAK1. If IRAK1 mRNA is a target for miR-K12-9,
then its relevance must be during the initial phases of infection in
primary cells before transformation into PEL, or perhaps in other
cell types (endothelial cells, macrophages).
IRAK1 also contributes to the risk for systemic lupus erythe-
matosus (29). It has been implicated in EBV LMP1 signaling
(23), but mutations in IRAK1 have not previously been associ-
ated with human lymphoma. A specific (Leu265Phe) mutation
in IRAK1’s binding partner MyD88 was seen in 29% of acti-
vated B-cell–like DLBCL (30) and in a subset of Waldenström
macroglobulinemia (31, 32). Finally, an IRAK1/4 inhibitor
showed activity against Waldenström macroglobulinemia and
myelodysplastic syndrome (33, 34). This work provides a rationale
for testing the same inhibitor in PEL. In a larger sense, it suggests
that inhibiting IRAK1/IRAK4/MyD88 immune signaling may
yield new treatments for a number of viral cancers.
Materials and Methods
Sample Collection and Processing. Fifteen PEL cell lines and one primary ex-
udate were used. We previously reported the CGH analysis for these samples
(5). We submitted two batches of samples for targeted region enrichment,
using the RainDance platform at Expression Analysis and then the enriched
DNA to Illumina sequencing at the University of North Carolina High
Throughput Sequencing Facility. The first batch contained eight tumor cell
lines, 2.5 μg DNA (BC1, BC2, BC5, BCBL1, BCLM, BCP1, JSC1, and VG1). The
second batch contained eight tumor cell lines with limited DNA amounts,
less than 2.5 μg (CRO-AP2, CRO-AP3, CRO-AP5, BC3, patient 1, HHB2, ISI1,
and TY1). After library preparation, we validated the samples, using Quant-
iT PicoGreen dsDNA (Invitrogen).
Enrichment and Sequencing. We used RainDance technology for sequence
enrichment (35) and TruSeq DNA Sample preparation Kit V2 (Illumina, cat-
alog number FC-121–2001) for library preparation. The genomic DNA was
sheared into 2–4-kb fragments, purified, and mixed with all of the PCR
reagents except the primers. The mixture then formed a template droplet
(∼18 pL) within the microfluidic chip. It was then combined with the primer
pair droplets at a 1:1 ratio and formed a single PCR droplet (∼26 pL). The
collection of the PCR droplets was amplified using Illumina paired-end PCR
primers, and then the PCR amplicons were purified and normalized to 10 nM
for next-generation sequencing.
For sequencing, we first used an IlluminaGenomeAnalyzer for single reads
with a target read length of 36 bp to verify the targeted regions were
covered. Our evaluation showed the enrichment was successful (Table 1).
Because this alone was not enough to make high confidence variant calls,
we resequenced the libraries by paired-end sequencing with a mean read
length of 100 bp, using the Illumina HiSEq.2000 platform.
Alignment and Variants Calling. Read mapper on CLC genomic workbench
version 5.5 (CLC Bio) was used to align all of the reads to the human reference
genome build 19 Homo_sapiens_chromosome_hg19_2011_07_29 (155,270,560
bp, NC_000023). CLC read mapper is a fast and accurate high-throughput
sequencing alignment tool that combines the Smith-Waterman algorithm for
accuracy and a heuristic algorithm for speed. Mapping reads to a reference
genome and contains three steps: preprocessing the input data, the actual
mapping, and postprocessing the mapping results. Those steps become one
integrated workflow in CLC genomic workbench software.
Mapping was done with a local alignment of reads to reference, in which
an aligned read must have at least 50% of the length mapped with at least
80% of similarity to the reference. Mismatch, insertion, and deletion were
allowed with a penalty score of 2 (a match is scored 1); any nonspecific
matches (reads matched to multiple places) were discarded.
Variant calling was done with quality-based variant detection in CLC
workbench. This tool is based on the Neighborhood Quality Standard al-
gorithm (36) and finds all variants that passed the quality filters and user-
specified thresholds. The minimum coverage was set to 4, and every position
in the radius of 5 from a variant had to be accessed on the basis of the
qualities; up to 2 mismatches and gaps were allowed for a variant call with
minimum of variant frequency set to 35%. CLC variant detection also
annotates where the mutation lies and the type of mutations (eg, amino
acid change, insertions, and deletions). We then used the R software envi-
ronment to further filter out the mutations by coverage, frequency, loca-
tion, and type.
The specific parameter settings were, for short reads, mismatch cost = 2
and limit = 8; and for long reads, similarity = 0.8, length fraction = 0.5,
insertion cost = 3, deletion cost = 2, and mismatch cost = 2. For paired
reads, minimal distance = 80 and maximal distance = 2,500. Common to
all were conflict resolution = vote, ignore nonspecific matches, no
masking of reference, and local alignment. For SVN call, we used window
Fig. 3. IRAK1 haplotypes. In addition to the common SNV, we also un-
covered multiple sample-specific SNVs across the IRAK1 coding sequence
(cds). These allowed us to establish SVN haplotypes in IRAK1 for each of the
samples. Shown are the positions of all SNVs across the IRAK1 targeted
regions on the x axis and the sample name on the y axis. Dots indicate a
nucleotide difference from the hg19 reference genome, and the color of
the dots indicates the number of reads covering that specific SNV on a log10
scale. Note that all nucleotide positions were covered in all cell lines. Note
that each cell line has a different SNV pattern, demonstrating the unique
origin of each of our samples.
Fig. 4. Expression of IRAK isoforms in PEL. (A) Shown is a Western blot of
multiple PEL samples (BCBL-1, BC-1, BCP-1) and the BJAB Burkitt lymphoma
cell line for total IRAK1, phosphoIRAK1T209, IRAK2, IRAK4, IRAK-M, and beta
actin. (B) Immunofluorescence of IRAK1 phosphorylation in BJAB and BC1
cells, using antibodies against the T209 phosphorylation site in IRAK1
(green) and LANA (red). Nuclear DNA is counterstained with DAPI (blue).
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length = 11, maximum gap and mismatch count = 2, minimum central
quality = 20, minimum average quality = 15, minimum coverage = 4,
minimum variant frequency = 35.0%, and maximum expected variations
(ploidy) = 2.
Sanger Sequencing. We validated missenses and frame shifts with a high
mutation rate using primer sets designed to cover the specific mutation
points. Amplicons were amplified by conventional PCR, using 2× GoTaq
Green Master Mix (Promega, catalog number M7122), and either directly
sent for sequencing or first cloned into pGEM-T Easy Vector System I
(Promega, catalog number A1360) and then subjected to Sanger sequenc-
ing, using T7 promoter and Sp6 reverse primers on three or more insert
positive clones (Eton Bioscience Inc or GENEWIZ Inc).
Affymetrix SNP Array Data Integration. Since we had previously analyzed
known SNPs on all cell lines (5), we had SNP calls available for each cell line
from Gene Expression Omnibus (GEO) entry GSE25839. The Affymetrix
Genome-Wide Human SNP 6.0 Array is a SNP-based microarray that features
1.8 million genetic markers, including 906,600 SNPs and 946,000 probes for
the detection of copy number variation. We downloaded and extracted the
ID_Ref for all SNPs from Affymetrix 6.0 dataset GPL6801. Then we extracted
the SNPs on chromosome X and obtained the forced SNP calls for each of the
samples. Next, we built an ID_Ref × PELline matrix and subjected it to un-
supervised clustering by cell line. Finally, we identified SNPs that were also
covered by the targeted amplification and sequencing to verify the se-
quencing recovered the SNP.
Expression Data Analysis for Mutates Genes. We downloaded the expression
profiling data by Affymetrix Array from the GEO database GSE2350 for the
following cell lines: AIDS-Burkitt lymphoma contains 7 samples, AIDS-
DLBCL-immunoblastic contains 9 samples, DLBCL-CB contains 23 samples,
DLBCL-immunoblastic contains 10 samples, and PEL contains 9 samples. All
of the original data files are in CEL format, so we first applied trans-
formation to the expression value by the standard Affymetrix normali-
zation method to eliminate bench effect, using the R packages “aroma.
affymetrix” and “affy” to preprocess the CEL files and export a text file
containing a table of estimated gene-level expression values. Then we
applied a hierarchical clustering algorithm to cluster the genes. Here we
have a matrix of expression values, in which rows are genes and columns
are cell lines. We applied hierarchical clustering coupled with Euclidean
distance to measure (dis)similarities and Wald linkage function to
group rows.
Cell Viability Assay. To check cell viability, BJAB and PEL (BCBL-1 and BC-1) cells
were cultured in 96-well plates (10,000 cells perwell) with RPMI (Gibco, 11875,
100 μL/mL), containing 2 mM L-glutamine, 10% FBS, penicillin G (100 U/mL),
and streptomycin sulfate (100 μg/mL) and supplemented with 0.05 mM
2-mercaptoethanol (Invitrogen, 21985–023), 0.075% sodium bicarbonate (Life
Technologies, 25080–094), and 1 U/mL human IL-6 (Peprotech, 200–06). Cells
were harvested for viability analysis on day 3, the substrate of CellTiter-Glo
(Promega, G7571) was added, and luminescent signals were measured by
FLUOstar Optima 96-well luminometer (BMG Labtech). Three independent
biological assays were performed for each experiment, and each measure-
ment was conducted in three technical replicates.
Il-6 and Il-10 ELISA. In a 12-well plate, 5 × 105/mL cells were seeded and
treated as indicated, and supernatants were collected. The levels of secreted
IL-10 were measured using commercial ELISA according to the manu-
facturer’s protocol (eBioscience).
Knockout of IRAK1 with shRNA Lentivirus. Two pLKO.1 lentiviral vectors
(TRCN000000121137 and TRCN000000121138) targeted for IRAK1 (GeneID
3654) were obtained from Open Biosystems/Thermo Inc. The reconstructed
lentiviruses were produced by the Lenti-shRNA Core Facility at the University
of North Carolina. BJAB and PEL cells (5 × 105) were grown in multiwell
plates, infected with 1 mL or 106 pfu lentiviruses (multiplicity of infection of
2) separately by adding Polybrene at a final concentration of 10 μg/mL, and
incubated at 37 °C for 6 h. After infection, medium was replaced with fresh
RPMI 1640 supplemented with 10% FBS and containing 2 mM L-glutamine,
penicillin G (100 U/mL), and streptomycin sulfate (100 μg/mL) and supple-
mented with 0.05 mM 2-mercaptoethanol (Invitrogen Inc.), 0.075% sodium
bicarbonate (Life Technologies, Inc.), and 1 U/mL human IL-6 (Peprotech,
Inc.). On day 2, puromycin (5 μg/mL) was added to the medium. GFP lenti-
virus (shRNA-GFP) was used as control.
Immunofluorescence. BJAB and BCBL-1 cells were fixed with 3% (wt/vol)
buffered paraformaldehyde for 20 min at room temperature (RT), per-
meabilized with 0.2% Triton X-100 in PBS for 15 min at 37 °C. Samples were
then immune-stained with rabbit anti-IRAK1 (Cell Signaling, catalog number
4504, at 1:200), anti-phosphoIRAK1 (T209, Cell Signaling, catalog number
12756, at 1:200), and mouse anti-LANA (NCL-HHV8-LNA, Leica, catalog
number NCL-HHV8-LNA at 1:500), for 2 h at RT, followed by incubation with
secondary antibody: Texas-Red anti-mouse IgG (Vector Laboratories, catalog
number TI-2000, at 1:1,000) or fluorescein anti-rabbit IgG (Vector Labora-
tories, catalog number FI-1000, at 1:1,000) for 60 min at RT in the dark.
Cells were washed three times with Tris-buffered saline and Tween 20, and
nuclei were stained with DAPI (Sigma, catalog number D9542 at 1:1,000).
Samples were observed with a fluorescence microscope type Leica DM4000B
and imaged using a 100 ×/1.40–0.7 oil numerical aperture objective and a
Q-Imaging Retiga 2000RV camera.
IL-1β Stimulation. Cells were treated with 10 ng/mL IL-1β (R&Ds System,
catalog number 210-LB) for 0, 15, 30, and 60 min, followed by Western
blotting assay with anti-IRAK1 (Cell Signaling catalog number 4504, at
1:1,000) and anti-phoshoIRAK1(T209) (Cell Signaling catalog number 12756,
at 1:1,000) antibodies. β-actin (Cell Signaling, catalog number A5441, at
1:3,000) was used as loading control. Signal was developed using Pierce ECL
Western blotting substrate (Thermo Scientific, catalog number 32209) and
recorded on film (Genesee Scientific, catalog number 30–101).
Fig. 5. Function of mutant IRAK1 in PEL. (A) BJAB and PEL cells were
stimulated with 10 ng/mL IL-1β for indicated amounts of time and protein
extracts were analyzed by Western blotting, using rabbit anti-IRAK1, anti-
phospho IRAK1 T209, and mouse anti-β-actin, followed by secondary HRP-
conjugated antibodies. (B) BJAB and PEL cells were fixed, permeabilized,
and stained with rabbit anti-IRAK1 and mouse anti-LANA monoclonal
antibodies, followed by fluorescence-conjugated secondary antibody.
Nucleus was stained blue with DAPI. (Magnification: 600×.). (C ) A panel of
PEL cell lines and the BJAB Burkitt lymphoma cell line were stimulated
with 10 ng/mL IL-1β for 30 min and analyzed as in A. (D) Cells viability was
analyzed with a CellTiter-Glo kit. BJAB and PEL cells were infected with
two independent shRNA-lentiviruses against IRAK1 for 4 d, and lumi-
nescence was measured. GFP shRNA lentiviruses were used as negative
controls. (E ) Result of colony formation assay at 10× and 40× magnifica-
tion of BJAB and BCBL-1 cells infected with IRAK1 shRNA lentivirus vector
and cultured under 5 μg/mL puromycin selection for 3 weeks. (F ) Re-
duction in secreted IL-10 accumulated for 4 d after infection with anti-
IRAK1 or anti-GFP shRNA for indicated cell lines. (G) Western blot of
IRAK1 levels at 4 d after infection with anti-IRAK1 or anti-GFP shRNA for
indicated cell lines.















Colony Formation. BJAB and PEL cells (5 × 105) were infected with shIRAK1
lentiviruses as described earlier. After 24 h, cells were mixed with Methocult
M3134 medium (Stemcell Technologies, catalog number 03134) (1:10) according
to manufacturer’s recommendation, puromycin (5 μg/mL) was added to the
medium, and the mixture was dispensed into a 35-mm culture dish (catalog
number 27100) by using a 3-mL syringe attached to a 16-gauge blunt-end
needle (catalog number 28110). After 3 weeks, colonies were observed un-
der dissecting microscope type Leica MZ6 (KL1500 LCD) with 1× objective
and 10× eyepieces and were imaged using a Leica DC 150 camera with 3,072 ×
2,304 pixel resolution.
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